Marzetti 10-Q Details Q1 FY2027: EPS $1.07, Gross Margin Down 110 bps to 23.0%
MZTI is trading near its 52-week low of $97 (6.2% above the low) on elevated volume (1.9× avg).
Summary
Marzetti's Q1 FY2027 10-Q shows the full damage behind this morning's headline: sales down 2.4% to $481.5 million, gross margin down 110 basis points to 23.0%, and diluted EPS of $1.07 versus $1.71, with the cyclospora outbreak, freight costs and Atlanta plant ramp cited as the drags.
Key Events · Earnings and Guidance · MZTI
-
Q1 EPS Falls to $1.07 From $1.71
Net sales fell 2.4% to $481.5 million and diluted EPS dropped to $1.07 from $1.71; adjusted diluted EPS was $1.14 versus $1.74.
-
Gross Margin Down 110 bps to 23.0%
Gross profit fell $8.0 million to $110.8 million on lower production volumes, higher freight and diesel costs, and Atlanta plant commissioning costs, partly offset by cost savings.
-
Cyclospora Outbreak Hits Both Segments
The outbreak is estimated to have cut Retail net sales by about 4% and Foodservice by about 2%; management says the impact has moderated in recent weeks.
-
Bachan's Adds $17.8M but Organic Retail Weak
Bachan's contributed $17.8 million of incremental Retail sales; excluding it, Retail sales volumes declined 7.1%.
Analysis · MZTI · Manufacturing
This morning's 8-K gave the headline; the 10-Q shows where the money went. Gross profit fell $8.0 million to $110.8 million as the cyclospora outbreak cut Retail sales about 4% and Foodservice about 2%, and gross margin dropped 110 basis points to 23.0% on lower production volumes plus higher diesel and freight costs. SG&A jumped 18.7% to $69.3 million, including $2.4 million of new Bachan's intangible amortization, so operating income fell 30.1% to $41.4 million and adjusted diluted EPS came in at $1.14 versus $1.74. The balance sheet is not stretched — $197.5 million of term loan at 5.0%, the $200 million revolver undrawn, and covenants met with substantial margin — but cash fell to $17.5 million from $25.1 million as operating cash flow slipped to $51.0 million and the company kept paying a $1.00 quarterly dividend and buying back stock. Management still guides to roughly $90 million of fiscal 2027 capex and expects to offset inflation with pricing and cost savings; the swing factor is how fast outbreak-related demand recovers.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MZTI was trading at $103.00 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $3B. The 52-week trading range was $97.00 to $176.26. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.